Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mahal

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Urologic Oncology|October 13, 2014
Income inequality and treatment of African American men with high-risk prostate cancerDavid R Ziehr, Brandon A Mahal, Ayal A Aizer, et al.
Journal of the National Cancer Institute|September 10, 2024
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancersAlexander G Goglia, Mohammed Alshalalfa, Anwar Khan, et al.
The Journal of Urology|February 15, 2015
Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate CancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2019
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer TypesWilliam S Chen, Mohammed Alshalalfa, Shuang G Zhao, et al.
Urologic Oncology|July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2014
Incidence and determinants of 1-month mortality after cancer-directed surgeryB A Mahal, G Inverso, A A Aizer, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2022
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysisShivanshu Awasthi, Brandon A Mahal, Jong Y Park, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Urologic Oncology|October 13, 2014
Income inequality and treatment of African American men with high-risk prostate cancerDavid R Ziehr, Brandon A Mahal, Ayal A Aizer, et al.
Journal of the National Cancer Institute|September 10, 2024
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancersAlexander G Goglia, Mohammed Alshalalfa, Anwar Khan, et al.
The Journal of Urology|February 15, 2015
Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate CancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2019
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer TypesWilliam S Chen, Mohammed Alshalalfa, Shuang G Zhao, et al.
Urologic Oncology|July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2014
Incidence and determinants of 1-month mortality after cancer-directed surgeryB A Mahal, G Inverso, A A Aizer, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2022
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysisShivanshu Awasthi, Brandon A Mahal, Jong Y Park, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Pageof 21